SCHEMBL17303552

SCHEMBL17303552

Cc1ccccc1S(=O)(=O)N1CCNCC1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKACA P17612 4/20 0.58
PRKCD Q05655 4/20 0.58
PRKD3 O94806 3/20 0.58
PRKACG P22612 3/20 0.58
PRKACB P22694 3/20 0.58
PRKCZ Q05513 3/20 0.58
PRKCG P05129 2/20 0.58
PRKCB P05771 2/20 0.58
PRKCA P17252 2/20 0.58
PRKCH P24723 2/20 0.58
PRKCI P41743 2/20 0.58
PRKCE Q02156 2/20 0.58
PRKCQ Q04759 2/20 0.58
PRKD1 Q15139 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
ALOX15 P16050 2/20 0.58
MEN1 O00255 1/20 0.58
TP53 P04637 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15917032 0.84 PRKACA (0.57) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL15917030 0.84 PRKACA (0.57) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL15917140 0.84 PRKACA (0.57) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL19287702 0.83 PRKACA (0.56) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL18672672 0.83 PRKACA (0.56) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL21566684 0.82 PRKACA (0.55) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL28257109 0.81 PRKACA (0.54) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL21124304 0.81 ACHE (0.57) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL5635569 0.81 L3MBTL1 (0.58) PRKACAPRKCDPRKD3PRKACGPRKACB
SCHEMBL16442259 0.81 L3MBTL1 (0.58) PRKACAPRKCDPRKD3PRKACGPRKACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2935247-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2019-08-28 EP disclosed
EP-2935243-B1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF EPIZYME INC (US) 2018-03-14 EP disclosed
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-11-23 US disclosed
US-9745291-B2 PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof Epizyme, Inc. (US) 2017-08-29 US disclosed
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2017-07-27 US disclosed
US-9604930-B2 Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof Epizyme, Inc. (US) 2017-03-28 US disclosed
US-20150344434-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2015-12-03 US disclosed
US-20150344433-A1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF Epizyme, Inc. (US) 2015-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344433-A1 PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF PRMT5, PRMT1, PRMT3 PRKACA 1089/4885PRKCD 1040/4885PRKD3 611/4885
US-20170334861-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 PRKACA 1083/4885PRKCD 1192/4885PRKD3 658/4885
US-20170210751-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT6 PRKACA 1269/4885PRKCD 1140/4885PRKD3 463/4885
US-20150344434-A1 TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT3 PRKACA 1020/4885PRKCD 1111/4885PRKD3 619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.